FDA Gives Green Signal To Second Omicron-Adapted Booster Shots For People At High Risk From Covid
-
On Tuesday, the FDA amended the emergency use authorizations (EUAs) of Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE), and BioNTech SE's (NASDAQ: BNTX) COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule.
-
This action includes authorizing the current bivalent vaccines (original and omicron BA.4/BA.5 strains) to be used for all doses administered to individuals six months of age and older, including for an additional dose or doses for certain populations.
-
The monovalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized in the U.S.